TNFSF13B and systemic lupus erythematosus: The efficacy of belimumab in reducing lupus activity was first shown in two phase III randomized, placebo-controlled clinical trials (10, 11), and patients with serological activity, high BAFF levels, low baseline B cell counts, limited or no organ damage and no exposure to tobacco were later demonstrated to be more benefited (60–67).